Effect of spermine on lipid profile and HDL functionality in the streptozotocin-induced diabetic rat model

Life Sciences

Volumn 82, Issue 5-6, 2008, Pages 301-307

  Jafarnejad, A ^a   Bathaie, S Z ^a   Nakhjavani, M ^b   Hassan, M Z ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cholesterol acyltransferase; Diabetes complication; Diabetes mellitus; HDL functionality; Lecithin; Lipid profile; Paraoxonase 1; Spermine

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SPERMINE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; MALE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTILIPEMIC AGENTS; ARYLDIALKYLPHOSPHATASE; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GLYCOSYLATION END PRODUCTS, ADVANCED; INSULIN; LIPID METABOLISM; LIPOPROTEINS, HDL; MALE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RATS; RATS, WISTAR; SPERMINE;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 38349081325     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.11.015     Document Type: Article

References (39)

1. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., and Durrington P.N. Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arteriosclerosis Thrombosis Vascular Biology 15 11 (1995) 1812-1818
2. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., and La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. The Journal of Clinical Investigation 101 8 (1998) 1581-1590
3. Burstein M., Scholnick H.R., and Morfin R. Rapid method for isolation of lipoproteins from human serum by precipitation with polyanions. Journal of Lipid Research 11 6 (1970) 583-595
4. Curtiss L.K., and Witztum J.L. Plasma apolipoproteins AI, AII, B, CI, and E are glucosylated in hyperglycemic diabetic subjects. Diabetes 34 5 (1985) 452-461
5. Dirican M., Serdar Z., Sarandol E., and Sumen-Gur E. Lecithin:cholesterol acyltransferase activity and cholesteryl ester transfer rate in patients with diabetes mellitus. Turkish Journal of Medical Sciences 33 2 (2003) 95-101
6. Ferretti G., Bacchetti T., Marchionni C., Caldarelli L., and Curatola G. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetologica 38 4 (2001) 163-169
7. Fournier N., Myara I., Atger V., and Moatti N. Reactivity of lecithin-cholesterol acyl transferase (LCAT) towards glycated high-density lipoproteins (HDL). Clinica Chimica Acta 234 1-2 (1995) 47-61
8. Fridewald W.J., Levy R.J., and Fredrikson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clinical Chemistry 18 6 (1972) 499-502
9. Gugliucci A. Polyamines as clinical laboratory tools. Clinica Chimica Acta 344 1-2 (2004) 23-35
10. Gugliucci A., and Menini T. The polyamines spermine and spermidine protect proteins from structural and functional damage by AGE precursors: a new role for old molecules?. Life Science 72 23 (2003) 2603-2616
11. Harding J.J., and Ganea E. Protection against glycation and similar post-translational modifications of proteins. Biochimica et Biophysica Acta 1764 9 (2006) 1436-1446
12. Jafarnejad A., Bathaie S.Z., Nakhjavani M., Hassan M.Z., and Banasadegh S. The improvement effect of L-Lys as a chemical chaperone on STZ-induced diabetic rats, protein structure and function. Diabetes Metabolism Research and Reviews 24 (2008) 64-73
13. Janne J., Alhonen L., and Leinonen P. Polyamines: from molecular biology to clinical applications. Annals Medicine 23 3 (1991) 241-259
14. Kalousova M., Skrha J., and Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiological Research 51 6 (2002) 597-604
15. La Du B.N. Human serum paraoxonase/arylesterase. In: Kalow W. (Ed). Pharmacogenetics of Drug Metabolism (1992), Pergamon Press, New York: NY 51-91
16. Leal L.I. Inhibition of in vitro pyrraline formation by L-arginine and polyamines. Biomedical Pharmacotherapy 58 10 (2004) 598-604
17. Lima V.L.M., Coelho L.C.B.B., Kennedy J.F., Owen J.S., and Dolphin P.J. Lecithin: cholesterol acyl transferase (LCAT) as a plasma glycoprotein: an overview. Carbohydrate Polymers 55 2 (2004) 179-191
18. 2, formation. Journal of Biological Chemistry 252 2 (1977) 560-562
19. Lockwood D.H., and East L.E. Studies of the insulin-like actions of polyamines on lipid and glucose metabolism in adipose tissue cells. Journal of Biological Chemistry 249 24 (1974) 7717-7722
20. Lyons T.J. Lipoprotein glycation and its metabolic consequences. Diabetes 41 Suppl. 2 (1992) 67-73
21. Mackness M.I., Arrol S., and Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Letters 286 1-2 (1991) 152-154
22. Mackness M.I., Harty D., Bhatnagar D., Winocour P.H., Arrol S., Ishola M., and Durrington P.N. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86 2-3 (1991) 193-199
23. Mackness M.I., Arrol S., Abbott C., and Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104 1-2 (1993) 129-135
24. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., and Hegele R.A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Current Opinion in Lipidology, 7 2 (1996) 69-76
25. Mackness B., Durrington P.N., Boulton A.J., Hine D., and Mackness M.I. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. European Journal of Clinical Investigation 32 4 (2002) 223-224
26. Mamo J.C., Szeto L., and Steiner G. Glycation of very low density lipoprotein from rat plasma impairs its catabolism. Diabetologia 33 6 (1990) 339-345
27. Mendez J.D., and Ramos G.H.B. Animal models in diabetes research. Archives of Medical Research 25 4 (1994) 367-375
28. Méndez J.D., and Leal I. Inhibition of in vitro pyrraline formation by L-arginine and polyamines. Biomedicine & Pharmacotherapy 58 10 (2004) 598-604
29. Méndez J.D., and Balderas F.L. Inhibition by L-arginine and spermidine of hemoglobin glycation and lipid peroxidation in rats with induced diabetes. Biomedicine & Pharmacotherapy 60 1 (2006) 26-31
30. Nobecourt E., Davies M.J., Brown B.E., Curtiss L.K., Bonnet D.J., Charlton F., Januszewski A.S., Jenkins A.J., Barter P.J., and Rye K.A. The impact of glycation on apolipoproteins A-I structure and its ability to activate lecithin: cholesterol acyltransferase. Diabetologia 50 3 (2007) 643-653
31. Perlmutter D.H. Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking. Pediatric Research 52 6 (2002) 832-836
32. Pruneta-Deloche V., Sassolas A., Dallinga-Thie G.M., Berthezène F., Ponsin G., and Moulin P. Alteration in lipoprotein lipase activity bound to triglyceride-rich lipoproteins in the postprandial state in type 2 diabetes. Journal of Lipid Research 45 5 (2004) 859-865
33. Rye K.A., Clay M.A., and Barter P.J. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 145 2 (1999) 227-238
34. Steinbrecher U.P., and Witztum J.L. Glycosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 33 2 (1984) 130-134
35. Til H.P., Falke H.E., Prinsen M.K., and Willems M.I. Acute and subacute toxicity of tyramine, spermidine, spermine, putrescine and cadaverine in rats. Food Chemistry and Toxicology 35 3-4 (1997) 337-348
36. Triau J.E., Arbetter J., and Schaefer E.J. Impaired hepatocytes binding, uptake and degradation of glucosylated low density lipoproteins. Biochimica et Biophysica Acta 877 3 (1986) 359-365
37. Veiraiah A. Hyperglycemia, lipoprotein glycation, and vascular disease. Angiology 56 4 (2005) 431-438
38. Welch W.J., and Brown C.R. Influence of molecular and chemical chaperones on protein folding. Cell Stress & Chaperones 1 2 (1996) 109-115
39. Witzum J.L., Mahoney E.M., Branks M.J., Fisher M., Elam R., and Steinberg D. Non-enzymatic glycosylation of low-density lipoprotein alters its biological activity. Diabetes 31 4 Pt 1 (1982) 283-291